title: Ultra-high level of serum soluble interleukin-2 receptor at diagnosis predicts poor outcome for angioimmunoblastic T-cell lymphoma.
abstract: Angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of non-Hodgkin lymphoma and displays an aggressive clinical course with poor outcome. To identify prognostic factors for AITL, we retrospectively analyzed 36 patients with AITL. The median age was 74 years with 83% of the patients having advanced stage. Eighty-three percent received CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone)-like chemotherapies, resulting in an overall response rate of 63%. With a median follow-up of 9 years, the estimated overall survival at 5 years was 33.3%. Median serum level of soluble interleukin-2 receptor (sIL-2R) was 5615 U/mL at diagnosis, and over 10 000 U/mL of sIL-2R was identified as a significant poor prognostic factor, independent of the International Prognostic Index, Prognostic Index for peripheral T-cell lymphoma and Prognostic index for AITL (hazard ratio [HR], 4.42; 95% confidence interval [CI], 1.49-13.11; log-rank, p < 0.01). Our study shows that an ultra-high level of serum sIL-2R at diagnosis is a significant poor prognostic biomarker for AITL.
authors.affiliation: a Department of Hematology , Hokkaido University Graduate School of Medicine , Sapporo , Japan.|b Department of Internal Medicine , Hakodate Municipal Hospital , Hakodate , Japan.
authors.forename: Souichi
authors.initials: S
authors.lastname: Shiratori
authors.affiliation: a Department of Hematology , Hokkaido University Graduate School of Medicine , Sapporo , Japan.
authors.forename: Mizuha
authors.initials: M
authors.lastname: Kosugi-Kanaya
authors.affiliation: a Department of Hematology , Hokkaido University Graduate School of Medicine , Sapporo , Japan.
authors.forename: Akio
authors.initials: A
authors.lastname: Shigematsu
authors.affiliation: c Fourth Department of Internal Medicine , Obihiro Kosei Hospital , Obihiro , Japan.
authors.forename: Hajime
authors.initials: H
authors.lastname: Kobayashi
authors.affiliation: d Department of Hematology , Sapporo City General Hospital , Sapporo , Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yamamoto
authors.affiliation: e Department of Hematology , Sapporo Hokuyu Hospital , Sapporo , Japan.
authors.forename: Naoki
authors.initials: N
authors.lastname: Kobayashi
authors.affiliation: f Department of Internal Medicine , Sapporo Kosei General Hospital , Sapporo , Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Iwasaki
authors.affiliation: g Department of Internal Medicine , Aiiku Hospital , Sapporo , Japan.
authors.forename: Akio
authors.initials: A
authors.lastname: Mori
authors.affiliation: h Department of Internal Medicine , Wakkanai City Hospital , Wakkanai , Japan.
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Kunieda
authors.affiliation: b Department of Internal Medicine , Hakodate Municipal Hospital , Hakodate , Japan.
authors.forename: Tsutsumi
authors.initials: T
authors.lastname: Yutaka
authors.affiliation: i Department of Hematology , National Hospital Organization Hokkaido Cancer Center , Sapporo , Japan.
authors.forename: Mitsutoshi
authors.initials: M
authors.lastname: Kurosawa
authors.affiliation: j Department of Hematology , Asahikawa City Hospital , Asahikawa , Japan.
authors.forename: Yasutaka
authors.initials: Y
authors.lastname: Kakinoki
authors.affiliation: a Department of Hematology , Hokkaido University Graduate School of Medicine , Sapporo , Japan.
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Endo
authors.affiliation: a Department of Hematology , Hokkaido University Graduate School of Medicine , Sapporo , Japan.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kondo
authors.affiliation: k Health Care Center, Hokkaido University , Sapporo , Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Hashino
authors.affiliation: a Department of Hematology , Hokkaido University Graduate School of Medicine , Sapporo , Japan.
authors.forename: Takanori
authors.initials: T
authors.lastname: Teshima
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D016399:Lymphoma, T-Cell / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011237:Predictive Value of Tests; D011239:Prednisolone / Q000008:administration & dosage; D011379:Prognosis; D015375:Receptors, Interleukin-2 / Q000097:blood*; D012189:Retrospective Studies; D012995:Solubility; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014408:Biomarkers, Tumor; D015375:Receptors, Interleukin-2; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone
keywords: Angioimmunoblastic T-cell lymphoma; non-Hodgkin lymphoma; peripheral T-cell lymphoma; prognostic factor; soluble interleukin-2 receptor